| Risk Dimension | Evidence Quality | Severity if Realized | Practical Impact | |---|---|---|---| | Absorption interference (oral, same-time dosing) | Indirect/mechanistic | Moderate (reduced efficacy) | High: fixable with timing | | Direct chelation (glutathione binds alendronate) | None documented | Low | Low | | Pharmacodynamic antagonism (bone) | None documented | Potentially none or positive | Low | | Hepatic CYP interaction | Not applicable | None | None | | Renal clearance competition (IV glutathione) | Theoretical only | Unknown | Moderate precaution warranted | The dominant clinical concern is absorption interference, and it is entirely preventable with correct timing
Chronic conditions involving persistent inflammation, incomplete tissue healing, or adaptive dysfunction respond well to the sustained gentle support that micro-dosing provides
Ye R, Ren A, Zhang L, et al
At week 20, they were randomized: half continued the 2.4 mg dose, half switched to placebo
Standard oral glutathione has a well-documented absorption problem, with research dating back decades showing much of it breaks down before reaching the bloodstream
